“Relative Symmetry with Electronegativity of Different Key-Groups” Strategy for MRGPRX2 Antagonist Design and Its Effect on Antigen-Induced Pulmonary Inflammation

Jiayu Lu,Zhaomin Xia,Yongjing Zhang,He Wang,Wen Yang,Siqi Wang,Nan Wang,Yun Liu,Huaizhen He,Cheng Wang,Langchong He

DOI: https://doi.org/10.1016/j.apsb.2024.11.023

IF: 14.903

2024-01-01

Acta Pharmaceutica Sinica B

Abstract:MRGPRX2 antagonists possess the potential for the treatment of allergic rhinitis, atopic dermatitis, and chronic urticaria. Previously, we identified a class of diaryl urea (DPU) MRGPRX2 antagonists with sub-micromolar IC50 values in vitro. However, the structure–activity relationship remains unclear. Herein, we adopted a “relative symmetry with electronegativity of different key-groups” strategy for further modification of DPUs to achieve a promising MRGPRX2 antagonist with higher activity and safety. Electrostatic potential energy analysis and biological evaluation revealed that B-1023 and B-5023, that possess relatively symmetric electron-withdrawing substituents, remarkable inhibited mast cell degranulation at a sub-micromolar IC50 in vitro and alleviated anaphylactic symptoms. Furthermore, B-1023, mitigated antigen-induced pulmonary inflammation (AIPI) in mice and competitively bonded to MRGPRX2. In summary, the “relative symmetry with electronegativity of different key-groups” strategy provided a drug design pattern for MRGPRX2 antagonists and identified promising antiallergic precursors for AIPI treatment.